Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
Carregando...
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2018
Editora
ASSOC ARQUIVOS NEURO- PSIQUIATRIA
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
BRANCO, Luciana Prats
ADONI, Torso
BROOKS, Joseph Bruno Bidin
CORREA, Eber Castro
DAMASCENO, Carlos Augusto
EBONI, Audred Cristina Biondo
FEZER, Leticia
GAMA, Paulo Diniz da
GONCALVES, Marcus Vinicius Magno
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
ARQUIVOS DE NEURO-PSIQUIATRIA, v.76, n.9, p.588-591, 2018
Resumo
Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.
Palavras-chave
multiple sclerosis, leukoencephalopathy, progressive multifocal, JC virus, natalizumab
Referências
- Alroughani R, 2018, MULT SCLER RELAT DIS, V20, P132, DOI 10.1016/j.msard.2018.01.016
- Alroughani R, 2016, J NEUROL SCI, V360, P61, DOI 10.1016/j.jns.2015.11.044
- Bellizzi Anna, 2013, Clin Dev Immunol, V2013, P839719, DOI 10.1155/2013/839719
- Bozic C, 2014, EUR J NEUROL, V21, P299, DOI 10.1111/ene.12304
- Paz SPC, 2018, EPIDEMIOL HEALTH, V40, DOI 10.4178/epih.e2018001
- Correia I, 2017, J CLIN NEUROSCI, V45, P257, DOI 10.1016/j.jocn.2017.08.006
- Engels EA, 2005, INT J CANCER, V117, P1013, DOI 10.1002/ijc.21277
- Fragoso YD, 2013, ARQ NEURO-PSIQUIAT, V71, P780, DOI 10.1590/0004-282X20130121
- Grabowski MK, 2009, J MED VIROL, V81, P1140, DOI 10.1002/jmv.21493
- Hegen H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174005
- Koralnik IJ, 2006, ANN NEUROL, V60, P162, DOI 10.1002/ana.20933
- Major E, 2018, LANCET NEUROL, V17, P467, DOI 10.1016/S1474-4422(18)30040-1
- McGuigan C, 2016, J NEUROL NEUROSUR PS, V87, P117, DOI 10.1136/jnnp-2015-311100
- Outteryck O, 2014, MULT SCLER J, V20, P822, DOI 10.1177/1352458513505353
- Peters J, 2017, J NEUROL, V264, P2409, DOI 10.1007/s00415-017-8643-4
- Schwab N, 2018, MULT SCLER J, V24, P563, DOI 10.1177/1352458517728814
- Schwab N, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000195
- Tan CS, 2010, J VIROL, V84, P9200, DOI 10.1128/JVI.00609-10
- Tan CS, 2010, LANCET NEUROL, V9, P425, DOI 10.1016/S1474-4422(10)70040-5
- van Kempen ZLE, 2017, EUR J NEUROL, V24, P1196, DOI 10.1111/ene.13355
- Vennegoor A, 2016, EUR J NEUROL, V23, P1079, DOI 10.1111/ene.12988